Register Now: Image-Based Risk: The Next Frontier in Breast Cancer Screening
|Articles|October 22, 2009

PET advocates press second scan coverage

The Centers for Medicare and Medicaid Services (CMS) believes one PET scan is enough when doing a patient’s initial treatment evaluation, but seven medical imaging groups disagree.

PET advocates press second scan coverage
The Centers for Medicare and Medicaid Services (CMS) believes one PET scan is enough when doing a patient’s initial treatment evaluation, but seven medical imaging groups disagree. The groups this week signed a joint letter to CMS formally requesting coverage of two fluorodeoxyglucose (FDG) scans per patient under certain circumstances. They argued that limiting coverage to just one may be contrary to good clinical practice. Three examples underscoring the need for a second initial FDG/PET scan were highlighted in the letter, signed by the leadership of the National Oncologic PET Registry Working Group, the Academy of Molecular Imaging, the American College of Nuclear Medicine, the American College of Radiology, the American Society for Radiation Oncology, the Institute for Molecular Technologies and SNM. The first addresses the use of PET for the diagnosis or staging of a tumor when the course of treatment is determined to be radiation therapy and another PET scan is needed for successful radiation therapy planning. The second is when PET returns a false-negative when evaluating a suspicious lesion for a patient later diagnosed with cancer and another scan is needed for staging before treatment. The third applies to patients with newly diagnosed cancer who had to delay treatment and another scan is required to evaluate the disease after a prolonged period of time.

Related to this article

Emerging Research Insights and New Advances in Neuroradiology
Catch up on key neuroradiology news and research from the past month, including recently published studies involving white matter hyperintensity findings on brain MRI, MRI-enhanced amyloid PET and the newly FDA-approved PET agent floretyrosine F18 for glioma imaging.
Current Perspectives on Integrating AI into Radiology
In a recent interview with Diagnostic Imaging, Joseph Cavallo, MD, MBA, offered insights on post-deployment monitoring with AI, the potential for improved workflow efficiency and the ongoing challenge of balancing essential clinical skills and AI literacy in the training of radiology residents and fellows.